Diabetes News

Endocrinology

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Anastasilakis AD et al. - Although effective as an antiresorptive agent, denosumab has not yet proved its efficacy on fracture risk reduction while increased infection risk questions its safety.

Related Articles

Osteologix to Continue Development of Osteoporosis Drug
Internet Source, 10/21/09    Relevance Score: 93%

Lifestyle increases osteoporosis risk: docs
Internet Source, 10/21/09    Relevance Score: 90%

Reducing hip fracture risk with risedronate in elderly women with established osteoporosis
Clinical Interventions in Aging, 11/12/09    Relevance Score: 89%

A microarray based identification of osteoporosis-related genes in primary culture of human osteoblasts
Bone, 10/27/09    Relevance Score: 89%

Evaluation of Compliance with Osteoporosis Treatment Guidelines After Initiation of a Pharmacist-Run Osteoporosis Service at a Family Medicine Clinic
Annals of Pharmacotherapy, 10/15/09    Relevance Score: 89%

Today in Pharmacology/kinetics...keeping you current

Treatment with alpha-lipoic acid reduces asymmetric dimethylarginine in patients with type 2 diabetes mellitus
Translational Research, The Journal of Laboratory and Clinical Medicine, 12/11/09

Insulin therapy in type 2 diabetes: insulin analogue mix 50, a potential role in reducing postprandial hyperglycaemia and cardiovascular disease
Expert Opinion in Pharmacotherapy, 12/11/09

Effect of Raloxifene on Serum Lipids for Type 2 Diabetic Menopausal Women with or without Statin Treatment
Medical Principles and Practice, 12/11/09


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Sponsor

Send this Summary to a Colleague

Enter email address